Director/PDMR Shareholding

RNS Number : 7360T

GlaxoSmithKline PLC

16 October 2017

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 1,605.036 £15.2750 831.931 £15.2750 2,740.030 £15.2750 4,439.830
d)	Aggregated information Aggregated volume Price	9,616.827 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R G Connor
b)	Position/status	President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 1,249.200 £15.2750 1,600.015 £15.2750 1,529.167
d)	Aggregated information Aggregated volume Price	4,378.382 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Debruyne
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 319.540 £15.2750 402.745 £15.2750 1,147.102
d)	Aggregated information Aggregated volume Price	1,869.387 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

 

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 2,716.836 £15.2750 2,942.442 £15.2750 2,427.360
d)	Aggregated information Aggregated volume Price	8,086.638 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 605.675 £15.2750 660.007 £15.2750 563.370
d)	Aggregated information Aggregated volume Price	1,829.052 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr B McNamara
b)	Position/status	CEO, GSK Consumer Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $41.02 415.800 $41.02 83.187 $41.02 641.729 $41.02 1,036.064
d)	Aggregated information Aggregated volume Price	2,176.780 $41.02
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 993.680 £15.2750 1,160.005 £15.2750 1,094.561
d)	Aggregated information Aggregated volume Price	3,248.246 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, HR
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 1,324.911 £15.2750 1,460.009 £15.2750 1,207.230
d)	Aggregated information Aggregated volume Price	3,992.150 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name		Mr P C Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment		Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name		GlaxoSmithKline plc
b)	LEI		5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument		Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction		Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)		Price(s) Volume(s) £15.2750 766.560 £15.2750 840.010 £15.2750 756.529
d)	Aggregated information Aggregated volume Price		2,363.099 £15.2750
e)	Date of the transaction		2017-10-12
f)	Place of the transaction		n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D E Troy
b)	Position/status	SVP & General Counsel
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $41.02 1,132.956 $41.02 1,314.438 $41.02 1,154.472
d)	Aggregated information Aggregated volume Price	3,601.866 $41.02
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr P J T Vallance
b)	Position/status	President, R&D
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 2,755.819 £15.2750 3,400.038 £15.2750 3,138.824
d)	Aggregated information Aggregated volume Price	9,294.681 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mrs V A Whyte
b)	Position/status	Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.2750 169.685 £15.2750 160.363 £15.2750 150.569
d)	Aggregated information Aggregated volume Price	480.617 £15.2750
e)	Date of the transaction	2017-10-12
f)	Place of the transaction	n/a

 

END

 

 

DSHEQLFFDBFXFBX